A new Consensus Statement has been issued as a result of a conference between the BTA, ATA and ETA liebertpub.com/doi/10.1089/... .
This document is a mix of some detailed technical information and recommendations for a future study (it seems the use of the singular ‘a’ is intended).
It has some good points: -
The introduction of better measures of outcomes in combination therapy studies.
Selecting patients who are dissatisfied with current treatment.
With LT4 monotherapy TSH is normalised before fT3.
TH action that relies on D2 generated T3 is at risk during LT4 monotherapy.
LT4 monotherapy may cause cancer – this is something I want to write up in the future.
On the other hand, there are some problems: -
By considering genetic issues they are unlikely to find out why patients become ill, as opposed to being ill from birth.
The ethos appears to be to target TSH, in diagnosis, therapy and study outcomes.
My major concern is that there is still a lack of basic science. Hypothyroidism is a clinical condition; it must be diagnosed on a clinical basis. It is essential to observe what therapies are effective, what doses of LT3 / LT4 for various patient groups. Once effective doses are identified we can then speculate about causes. All studies so far have assumed TSH reflects clinical status (it does not) and assumed normalising serum hormone levels is an appropriate target (it is not).
There is a need to take thyroid science a step further, to acknowledge thyroid hormone action as the prime target. Most T3 comes from cells that express type-2 deiodinase (D2), these cells rely on this T3 and release it into circulation. There is a misconception that patients with impaired D2 activity can be brought back to good health by simply giving some T3 to normalise serum fT3. This is wrong! It does little to restore the T3 missing from these cells.
Whilst this document is a step forward there is still a fundamental failure to grasp basic principles of science. The theory must follow observations, normal TSH, fT3, fT4 does not guarantee euthyroidism in all cases.